Updated Jul 16, 2026
Teel Randy has filed 2 SEC Form 4 filings across 1 company in the last 90 days — selling. Lifetime open-market sales: $226K.

Randy Teel is the President and CEO of Arvinas, Inc., a biotechnology company focused on developing therapies for cancer and other diseases through the use of targeted protein degradation. He has a background in the pharmaceutical and biotechnology industries, with extensive experience in drug development and corporate leadership.
| Role | President and CEO, Director |
|---|---|
| Notability | 75/100 |
| Date | Ticker | Company | Code | Shares | Price | Value |
|---|---|---|---|---|---|---|
| 2026-05-22 | ARVN | ARVINAS, INC. | S — Open-market sale | 2.2K | $9.04 | $20K |
| 2026-05-13 | ARVN | ARVINAS, INC. | S — Open-market sale | 9.7K | $9.94 | $96K |
| 2026-03-12 | ARVN | ARVINAS, INC. | A — Grant or award | 147.2K | $0.00 | |
| 2026-03-03 | ARVN | ARVINAS, INC. | A — Grant or award | 147.8K | $0.00 | |
| 2026-02-25 | ARVN | ARVINAS, INC. | S — Open-market sale | 3.7K | $12.16 | $46K |
| 2026-02-25 | ARVN | ARVINAS, INC. | S — Open-market sale | 1.0K | $12.16 | $13K |
| 2026-02-18 | ARVN | ARVINAS, INC. | S — Open-market sale | 4.4K | $11.89 | $52K |
Randy Teel is the President and CEO of Arvinas, Inc., a biotechnology company focused on developing therapies for cancer and other diseases through the use of targeted protein degradation. He has a background in the pharmaceutical and biotechnology industries, with extensive experience in drug development and corporate leadership.…
2 primary Form 4 filings in the last 90 days, covering 1 company.
Recorded transactions: 0 open-market purchases () and 5 open-market sales ($226K) across all tracked filings.
All Form 4 filings, transaction values, and 10b5-1 plan flags are listed on this page and updated in real time as new SEC EDGAR filings are processed.
Open the live Teel Randy profile on InsiderAlpha for real-time alerts, AI-scored trade ideas, and full transaction history.